MEIP - MEIファ―マ (MEI Pharma Inc.)

MEIPのニュース

   7-DAY DEADLINE ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against MEI Pharma, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm  2020/10/02 13:47:13 NewMediaWire
Los Angeles, CA - (NewMediaWire) - October 2, 2020 - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against MEI Pharma, Inc. (“MEI Pharma” or “the Company”) (NASDAQ: MEIP) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between August 2, 2017 and July 1, 2020, inclusive (the ''Class Period''), are encouraged to contact the firm before October 9, 2020. If you are a shareholder who suffered a loss, click here to participate. We also encourage you to contact Brian Schall of the Schall Law Firm, 1880 Century Park East, Suite 404, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at brian@schallfirm.com. The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney.
   ROSEN, A LEADING LAW FIRM, Reminds MEI Pharma, Inc. Investors of Important October 9 Deadline in Securities Class Action - MEIP  2020/09/29 00:47:00 PR Newswire
NEW YORK, Sept. 28, 2020 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of MEI Pharma, Inc. (NASDAQ: MEIP) between August 2, 2017 and July 1, 2020, inclusive (the "Class Period"), of the important October 9, 2020 lead plaintiff…
   MEI Pharma (MEIP) Presents At H.C. Wainwright 22nd Annual Global Investment Conference - Slideshow (NASDAQ:MEIP)  2020/09/17 18:33:52 Seeking Alpha
The following slide deck was published by MEI Pharma, Inc. in conjunction with this event..
   MEI Pharma Appoints Brian T. Powl As Senior Vice President, Marketing  2020/09/15 12:00:00 PR Newswire
SAN DIEGO, Sept. 15, 2020 /PRNewswire/ -- MEI Pharma, Inc. (NASDAQ: MEIP) ("MEI"), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today announced the appointment of Brian T. Powl as senior vice president, marketing, a new role that will report to David…
   ROSEN, RECOGNIZED INVESTOR COUNSEL, Reminds MEI Pharma, Inc. Investors of Important October 9 Deadline in Securities Class Action - MEIP  2020/09/14 20:32:00 PR Newswire
NEW YORK, Sept. 14, 2020 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of MEI Pharma, Inc. (NASDAQ: MEIP) between August 2, 2017 and July 1, 2020, inclusive (the "Class Period"), of the important October 9, 2020 lead plaintiff…
   ROSEN, A TOP RANKED LAW FIRM, Reminds MEI Pharma, Inc. Investors of Important October 9 Deadline in Securities Class Action – MEIP  2020/09/10 22:40:00 Business Wire
NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of MEI Pharma, Inc. (NASDAQ: MEIP) between August 2, 2017 and July 1, 2020, inclusive (the “Class Period”), of the important October 9, 2020 lead plaintiff deadline in the securities class action. The lawsuit seeks to recover damages for MEI Pharma investors under the federal securities laws. To join the MEI Pharma class action, go to http://www.rosenlegal.com/cases-register-1919.h
   MEI Pharma to Present at Upcoming Investor Conferences in September  2020/09/04 12:00:00 PR Newswire
SAN DIEGO, Sept. 4, 2020 /PRNewswire/ -- MEI Pharma, Inc. (NASDAQ: MEIP) ("MEI"), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today announced its participation in the following upcoming virtual investor conferences: Wells Fargo 2020 Virtual…
   MEI Pharma to Release 2020 Fiscal Year End Financial Results and Provide Corporate Update on September 9, 2020  2020/09/02 12:00:00 PR Newswire
SAN DIEGO, Sept. 2, 2020 /PRNewswire/ -- MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today announced that the Company will release its 2020 fiscal year end financial results after the close of the U.S. financial…
   Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against MEI Pharma, Cabot Oil & Gas, Kodak, and Genius Brands and Encourages Investors to Contact the Firm  2020/08/26 18:00:00 Benzinga
NEW YORK, Aug. 26, 2020 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that …
   Shareholder Alert: Robbins LLP Announces MEI Pharma, Inc. (MEIP) Accused of Misleading Shareholders  2020/08/12 22:35:00 Business Wire
SAN DIEGO--(BUSINESS WIRE)---- $MEIP #ClassAction--Shareholder rights law firm Robbins LLP announces that a purchaser of MEI Pharma, Inc. (NASDAQ: MEIP) filed a class action complaint against the Company for alleged violations of the Securities Exchange Act of 1934 between August 2, 2017 and July 1, 2020. MEI Pharma is a late-stage pharmaceutical company that focuses on the development of various therapies for the treatment of cancer. One of MEI Pharma's drug candidates is Pracinostat, an oral histone deacetylase (“H
   Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against MEI Pharma, Cabot Oil & Gas, Kodak, and Genius Brands and Encourages Investors to Contact the Firm  2020/08/26 18:00:00 Benzinga
NEW YORK, Aug. 26, 2020 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that …
   Shareholder Alert: Robbins LLP Announces MEI Pharma, Inc. (MEIP) Accused of Misleading Shareholders  2020/08/12 22:35:00 Business Wire
SAN DIEGO--(BUSINESS WIRE)---- $MEIP #ClassAction--Shareholder rights law firm Robbins LLP announces that a purchaser of MEI Pharma, Inc. (NASDAQ: MEIP) filed a class action complaint against the Company for alleged violations of the Securities Exchange Act of 1934 between August 2, 2017 and July 1, 2020. MEI Pharma is a late-stage pharmaceutical company that focuses on the development of various therapies for the treatment of cancer. One of MEI Pharma's drug candidates is Pracinostat, an oral histone deacetylase (“H
   SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against MEI Pharma, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm  2020/08/11 16:47:00 Business Wire
LOS ANGELES--(BUSINESS WIRE)---- $MEIP #MEIP--SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against MEI Pharma, Inc.
   MEIP Investor Alert: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of MEI Pharma, Inc. and Encourages Investors to Contact the Firm  2020/07/06 15:00:00 PR Newswire
NEW YORK, July 6, 2020 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of MEI Pharma, Inc. ("MEI Pharma" or "the Company") (NASDAQ: MEIP). Investors who purchased MEI Pharma securities are encouraged to…
   The Daily Biotech Pulse: MediciNova On Track For European Patent Win, Partial Clinical Hold Lifted For Innate Pharma, Tela Bio Details Coronavirus Impact  2020/06/24 12:07:18 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 23) ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD ) Acceleron Pharma Inc (NASDAQ: XLRN ) ADC Therapeutics SA (NYSE: ADCT ) Adverum Biotechnologies Inc (NASDAQ: ADVM ) Aeglea Bio Therapeutics Inc (NASDAQ: AGLE ) Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY ) Amicus Therapeutics, Inc. (NASDAQ: FOLD ) Ascendis Pharma A/S (NASDAQ: ASND ) Avidity Biosciences Inc (NASDAQ: RNA ) (went public June 12) BioXcel Therapeutics Inc (NASDAQ: BTAI ) Burning Rock Biotech Ltd (NASDAQ: BNR ) (went public June 12) Corcept Therapeutics Incorporated (NASDAQ: CORT ) Crispr Therapeutics AG (NASDAQ: CRSP ) (moved on analyst action) Dr.Reddy's Laboratories Ltd (NYSE: RDY ) Dyadic International, Inc. (NASDAQ: DYAI ) Editas Medicine Inc (NASDAQ: EDIT ) GENMAB A/S/S ADR (NASDAQ: GMAB ) Halozyme Therapeutics, Inc. (NASDAQ: HALO ) ) Hologic, Inc. (NASDAQ: HOLX ) Horizon Therapeutics PLC (NASDAQ: HZNP ) Immunomedics, Inc.

calendar